Diverse functions of matrix metalloproteinases during fibrosis

Matthew Giannandrea, William C Parks, Matthew Giannandrea, William C Parks

Abstract

Fibrosis--a debilitating condition that can occur in most organs - is characterized by excess deposition of a collagen-rich extracellular matrix (ECM). At first sight, the activities of proteinases that can degrade matrix, such as matrix metalloproteinases (MMPs), might be expected to be under-expressed in fibrosis or, if present, could function to resolve the excess matrix. However, as we review here, some MMPs are indeed anti-fibrotic, whereas others can have pro-fibrotic functions. MMPs modulate a range of biological processes, especially processes related to immunity and tissue repair and/or remodeling. Although we do not yet know precisely how MMPs function during fibrosis--that is, the protein substrate or substrates that an individual MMP acts on to effect a specific process--experiments in mouse models demonstrate that MMP-dependent functions during fibrosis are not limited to effects on ECM turnover. Rather, data from diverse models indicate that these proteinases influence cellular activities as varied as proliferation and survival, gene expression, and multiple aspects of inflammation that, in turn, impact outcomes related to fibrosis.

Keywords: Collagen; Extracellular matrix; Fibrosis; Metalloproteinase; TIMP.

Figures

Fig. 1.
Fig. 1.
Model of the roles of MMPs and TIMPs in fibrosis. In this schematic, the pathogenesis of mammalian fibrosis is broken down into four sequential events, operating over a timescale of weeks to months in animal models and longer in human conditions. First, injury or some sort of damage initiates tissue remodeling responses. Second, an influx of inflammatory cells and the expression of cytokines by both resident and immune cells contribute to the third stage – activation of myofibroblasts and excessive deposition of extracellular collagen, giving the typical appearance of fibrosis. Finally, during the resolution phase, myofibroblasts undergo apoptosis or deactivation, and excess collagen and other matrix components are degraded and cleared. The clearance process can be delayed or inhibited, leading to chronic fibrotic disease, tissue malfunction, organ stress and, ultimately, end-stage disease. By either promoting (arrows) or antagonizing (T-shapes) these processes, specific MMPs and TIMPs have net pro-fibrotic (upper section) or anti-fibrotic (lower section) properties. (See Table 1 or text for references.)

References

    1. Abraham A. P., Ma F. Y., Mulley W. R., Ozols E., Nikolic-Paterson D. J. (2012). Macrophage infiltration and renal damage are independent of matrix metalloproteinase 12 in the obstructed kidney. Nephrology (Carlton) 17, 322–329
    1. Aimes R. T., Quigley J. P. (1995). Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J. Biol. Chem. 270, 5872–5876
    1. Balbín M., Fueyo A., Knäuper V., López J. M., Alvarez J., Sánchez L. M., Quesada V., Bordallo J., Murphy G., López-Otín C. (2001). Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J. Biol. Chem. 276, 10253–10262
    1. Balbín M., Fueyo A., Tester A. M., Pendás A. M., Pitiot A. S., Astudillo A., Overall C. M., Shapiro S. D., López-Otín C. (2003). Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet. 35, 252–257
    1. Benyon R. C., Hovell C. J., Da Gaça M., Jones E. H., Iredale J. P., Arthur M. J. (1999). Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology 30, 977–986
    1. Betsuyaku T., Fukuda Y., Parks W. C., Shipley J. M., Senior R. M. (2000). Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am. J. Pathol. 157, 525–535
    1. Cabrera S., Gaxiola M., Arreola J. L., Ramírez R., Jara P., D’Armiento J., Richards T., Selman M., Pardo A. (2007). Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin. Int. J. Biochem. Cell Biol. 39, 2324–2338
    1. Carew R. M., Wang B., Kantharidis P. (2012). The role of EMT in renal fibrosis. Cell Tissue Res. 347, 103–116
    1. Chen P., Parks W. C. (2009). Role of matrix metalloproteinases in epithelial migration. J. Cell. Biochem. 108, 1233–1243
    1. Chen P., McGuire J. K., Hackman R. C., Kim K. H., Black R. A., Poindexter K., Yan W., Liu P., Chen A. J., Parks W. C., et al. (2008). Tissue inhibitor of metalloproteinase-1 moderates airway re-epithelialization by regulating matrilysin activity. Am. J. Pathol. 172, 1256–1270
    1. Chen P., Abacherli L. E., Nadler S. T., Wang Y., Li Q., Parks W. C. (2009). MMP7 shedding of syndecan-1 facilitates re-epithelialization by affecting alpha(2)beta(1) integrin activation. PLoS ONE 4, e6565.
    1. Chevalier R. L. (2006). Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat. Clin. Pract. Nephrol. 2, 157–168
    1. Chiaramonte M. G., Cheever A. W., Malley J. D., Donaldson D. D., Wynn T. A. (2001). Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology 34, 273–282
    1. Chow F. Y., Nikolic-Paterson D. J., Atkins R. C., Tesch G. H. (2004). Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol. Dial. Transplant. 19, 2987–2996
    1. Chu A. S., Diaz R., Hui J. J., Yanger K., Zong Y., Alpini G., Stanger B. Z., Wells R. G. (2011). Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 53, 1685–1695
    1. Conway B., Hughes J. (2012). Cellular orchestrators of renal fibrosis. QJM 105, 611–615
    1. Corry D. B., Kiss A., Song L. Z., Song L., Xu J., Lee S. H., Werb Z., Kheradmand F. (2004). Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines. FASEB J. 18, 995–997
    1. Craig V. J., Quintero P. A., Fyfe S. E., Patel A. S., Knolle M. D., Kobzik L., Owen C. A. (2013). Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injury. J. Immunol. 190, 4283–4296
    1. Datta A., Scotton C. J., Chambers R. C. (2011). Novel therapeutic approaches for pulmonary fibrosis. Br. J. Pharmacol. 163, 141–172
    1. Degryse A. L., Tanjore H., Xu X. C., Polosukhin V. V., Jones B. R., McMahon F. B., Gleaves L. A., Blackwell T. S., Lawson W. E. (2010). Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am. J. Physiol. 299, L442–L452
    1. Duffield J. S., Park K. M., Hsiao L. L., Kelley V. R., Scadden D. T., Ichimura T., Bonventre J. V. (2005). Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J. Clin. Invest. 115, 1743–1755
    1. Duffield J. S., Lupher M., Thannickal V. J., Wynn T. A. (2013). Host responses in tissue repair and fibrosis. Annu. Rev. Pathol. 8, 241–276
    1. Dunsmore S. E., Saarialho-Kere U. K., Roby J. D., Wilson C. L., Matrisian L. M., Welgus H. G., Parks W. C. (1998). Matrilysin expression and function in airway epithelium. J. Clin. Invest. 102, 1321–1331
    1. Eddy A. A., Kim H., López-Guisa J., Oda T., Soloway P. D. (2000). Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. Kidney Int. 58, 618–628
    1. Egeblad M., Werb Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161–174
    1. Endo H., Niioka M., Sugioka Y., Itoh J., Kameyama K., Okazaki I., Ala-Aho R., Kähäri V. M., Watanabe T. (2011). Matrix metalloproteinase-13 promotes recovery from experimental liver cirrhosis in rats. Pathobiology 78, 239–252
    1. England K. A., Price A. P., Tram K. V., Shapiro S. D., Blazar B. R., Panoskaltsis-Mortari A. (2011). Evidence for early fibrosis and increased airway resistance in bone marrow transplant recipient mice deficient in MMP12. Am. J. Physiol. 301, L519–L526
    1. Fallowfield J. A., Mizuno M., Kendall T. J., Constandinou C. M., Benyon R. C., Duffield J. S., Iredale J. P. (2007). Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J. Immunol. 178, 5288–5295
    1. Flechsig P., Hartenstein B., Teurich S., Dadrich M., Hauser K., Abdollahi A., Gröne H. J., Angel P., Huber P. E. (2010). Loss of matrix metalloproteinase-13 attenuates murine radiation-induced pulmonary fibrosis. Int. J. Radiat. Oncol. Biol. Phys. 77, 582–590
    1. Foronjy R. F., Sun J., Lemaitre V., D’Armiento J. M. (2008). Transgenic expression of matrix metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model. Hypertens. Res. 31, 725–735
    1. Garbacki N., Di Valentin E., Piette J., Cataldo D., Crahay C., Colige A. (2009). Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling? Pulm. Pharmacol. Ther. 22, 267–278
    1. García-Prieto E., González-López A., Cabrera S., Astudillo A., Gutiérrez-Fernández A., Fanjul-Fernandez M., Batalla-Solís E., Puente X. S., Fueyo A., López-Otín C., et al. (2010). Resistance to bleomycin-induced lung fibrosis in MMP-8 deficient mice is mediated by interleukin-10. PLoS ONE 5, e13242.
    1. Gill S. E., Parks W. C. (2008). Metalloproteinases and their inhibitors: regulators of wound healing. Int. J. Biochem. Cell Biol. 40, 1334–1347
    1. Gill S. E., Huizar I., Bench E. M., Sussman S. W., Wang Y., Khokha R., Parks W. C. (2010a). Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury. Am. J. Pathol. 176, 64–73
    1. Gill S. E., Kassim S. Y., Birkland T. P., Parks W. C. (2010b). Mouse models of MMP and TIMP function. Methods Mol. Biol. 622, 31–52
    1. Gough P. J., Gomez I. G., Wille P. T., Raines E. W. (2006). Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Invest. 116, 59–69
    1. Greenlee K. J., Corry D. B., Engler D. A., Matsunami R. K., Tessier P., Cook R. G., Werb Z., Kheradmand F. (2006). Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J. Immunol. 177, 7312–7321
    1. Hadler-Olsen E., Fadnes B., Sylte I., Uhlin-Hansen L., Winberg J. O. (2011). Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 278, 28–45
    1. Hernandez-Barrantes S., Toth M., Bernardo M. M., Yurkova M., Gervasi D. C., Raz Y., Sang Q. A., Fridman R. (2000). Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J. Biol. Chem. 275, 12080–12089
    1. Hu Y. B., Li D. G., Lu H. M. (2007). Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J. Gene Med. 9, 217–229
    1. Hu J. H., Du L., Chu T., Otsuka G., Dronadula N., Jaffe M., Gill S. E., Parks W. C., Dichek D. A. (2010). Overexpression of urokinase by plaque macrophages causes histological features of plaque rupture and increases vascular matrix metalloproteinase activity in aged apolipoprotein e-null mice. Circulation 121, 1637–1644
    1. Huang S. K., White E. S., Wettlaufer S. H., Grifka H., Hogaboam C. M., Thannickal V. J., Horowitz J. C., Peters-Golden M. (2009). Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J. 23, 4317–4326
    1. Hung C., Linn G., Chow Y. H., Kobayashi A., Mittelsteadt K., Altemeier W. A., Gharib S. A., Schnapp L. M., Duffield J. S. (2013). Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 188, 820–830
    1. Iimuro Y., Brenner D. A. (2008). Matrix metalloproteinase gene delivery for liver fibrosis. Pharm. Res. 25, 249–258
    1. Iimuro Y., Nishio T., Morimoto T., Nitta T., Stefanovic B., Choi S. K., Brenner D. A., Yamaoka Y. (2003). Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 124, 445–458
    1. Iwano M., Plieth D., Danoff T. M., Xue C., Okada H., Neilson E. G. (2002). Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110, 341–350
    1. Jirouskova M., Zbodakova O., Gregor M., Chalupsky K., Sarnova L., Hajduch M., Ehrmann J., Jirkovska M., Sedlacek R. (2012). Hepatoprotective effect of MMP-19 deficiency in a mouse model of chronic liver fibrosis. PLoS ONE 7, e46271.
    1. Kaar J. L., Li Y., Blair H. C., Asche G., Koepsel R. R., Huard J., Russell A. J. (2008). Matrix metalloproteinase-1 treatment of muscle fibrosis. Acta Biomater. 4, 1411–1420
    1. Kang H. R., Cho S. J., Lee C. G., Homer R. J., Elias J. A. (2007). Transforming growth factor (TGF)-beta1 stimulates pulmonary fibrosis and inflammation via a Bax-dependent, bid-activated pathway that involves matrix metalloproteinase-12. J. Biol. Chem. 282, 7723–7732
    1. Kassiri Z., Oudit G. Y., Kandalam V., Awad A., Wang X., Ziou X., Maeda N., Herzenberg A. M., Scholey J. W. (2009). Loss of TIMP3 enhances interstitial nephritis and fibrosis. J. Am. Soc. Nephrol. 20, 1223–1235
    1. Kaviratne M., Hesse M., Leusink M., Cheever A. W., Davies S. J., McKerrow J. H., Wakefield L. M., Letterio J. J., Wynn T. A. (2004). IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J. Immunol. 173, 4020–4029
    1. Kawamoto H., Yasuda O., Suzuki T., Ozaki T., Yotsui T., Higuchi M., Rakugi H., Fukuo K., Ogihara T., Maeda N. (2006). Tissue inhibitor of metalloproteinase-3 plays important roles in the kidney following unilateral ureteral obstruction. Hypertens. Res. 29, 285–294
    1. Kim H., Oda T., López-Guisa J., Wing D., Edwards D. R., Soloway P. D., Eddy A. A. (2001). TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 12, 736–748
    1. Kim K. H., Burkhart K., Chen P., Frevert C. W., Randolph-Habecker J., Hackman R. C., Soloway P. D., Madtes D. K. (2005). Tissue inhibitor of metalloproteinase-1 deficiency amplifies acute lung injury in bleomycin-exposed mice. Am. J. Respir. Cell Mol. Biol. 33, 271–279
    1. Kim K. K., Kugler M. C., Wolters P. J., Robillard L., Galvez M. G., Brumwell A. N., Sheppard D., Chapman H. A. (2006). Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. USA 103, 13180–13185
    1. Kim E. J., Cho H. J., Park D., Kim J. Y., Kim Y. B., Park T. G., Shim C. K., Oh Y. K. (2011). Antifibrotic effect of MMP13-encoding plasmid DNA delivered using polyethylenimine shielded with hyaluronic acid. Mol. Ther. 19, 355–361
    1. Kisseleva T., Brenner D. A. (2007). Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J. Gastroenterol. Hepatol. 22 Suppl., S73–S78
    1. Kolodsick J. E., Peters-Golden M., Larios J., Toews G. B., Thannickal V. J., Moore B. B. (2003). Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am. J. Respir. Cell Mol. Biol. 29, 537–544
    1. Kriz W., Kaissling B., Le Hir M. (2011). Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J. Clin. Invest. 121, 468–474
    1. Lanone S., Zheng T., Zhu Z., Liu W., Lee C. G., Ma B., Chen Q., Homer R. J., Wang J., Rabach L. A., et al. (2002). Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J. Clin. Invest. 110, 463–474
    1. LeBleu V. S., Taduri G., O’Connell J., Teng Y., Cooke V. G., Woda C., Sugimoto H., Kalluri R. (2013). Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047–1053
    1. Lee C. G., Homer R. J., Zhu Z., Lanone S., Wang X., Koteliansky V., Shipley J. M., Gotwals P., Noble P., Chen Q., et al. (2001). Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J. Exp. Med. 194, 809–821
    1. Leeming D., He Y., Veidal S., Nguyen Q., Larsen D., Koizumi M., Segovia-Silvestre T., Zhang C., Zheng Q., Sun S., et al. (2011). A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 16, 616–628
    1. Li Q., Park P. W., Wilson C. L., Parks W. C. (2002). Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111, 635–646
    1. Lin S. L., Kisseleva T., Brenner D. A., Duffield J. S. (2008). Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617–1627
    1. Liu Y. (2010). New insights into epithelial-mesenchymal transition in kidney fibrosis. J. Am. Soc. Nephrol. 21, 212–222
    1. Liu Y. (2011). Cellular and molecular mechanisms of renal fibrosis. Nat. Rev. Nephrol. 7, 684–696
    1. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., Abraham J., Adair T., Aggarwal R., Ahn S. Y., et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128
    1. Madala S. K., Pesce J. T., Ramalingam T. R., Wilson M. S., Minnicozzi S., Cheever A. W., Thompson R. W., Mentink-Kane M. M., Wynn T. A. (2010). Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. J. Immunol. 184, 3955–3963
    1. Manicone A. M., McGuire J. K. (2008). Matrix metalloproteinases as modulators of inflammation. Semin. Cell Dev. Biol. 19, 34–41
    1. Manicone A. M., Huizar I., McGuire J. K. (2009). Matrilysin (Matrix Metalloproteinase-7) regulates anti-inflammatory and antifibrotic pulmonary dendritic cells that express CD103 (alpha(E)beta(7)-integrin). Am. J. Pathol. 175, 2319–2331
    1. Manoury B., Nenan S., Guenon I., Boichot E., Planquois J. M., Bertrand C. P., Lagente V. (2006). Macrophage metalloelastase (MMP-12) deficiency does not alter bleomycin-induced pulmonary fibrosis in mice. J. Inflamm. (Lond) 3, 2.
    1. Matute-Bello G., Wurfel M. M., Lee J. S., Park D. R., Frevert C. W., Madtes D. K., Shapiro S. D., Martin T. R. (2007). Essential role of MMP-12 in Fas-induced lung fibrosis. Am. J. Respir. Cell Mol. Biol. 37, 210–221
    1. McCawley L. J., Matrisian L. M. (2001). Matrix metalloproteinases: they’re not just for matrix anymore! Curr. Opin. Cell Biol. 13, 534–540
    1. McGuire J. K., Li Q., Parks W. C. (2003). Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am. J. Pathol. 162, 1831–1843
    1. McQuibban G. A., Gong J. H., Tam E. M., McCulloch C. A., Clark-Lewis I., Overall C. M. (2000). Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202–1206
    1. McQuibban G. A., Butler G. S., Gong J. H., Bendall L., Power C., Clark-Lewis I., Overall C. M. (2001). Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 276, 43503–43508
    1. McQuibban G. A., Gong J. H., Wong J. P., Wallace J. L., Clark-Lewis I., Overall C. M. (2002). Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100, 1160–1167
    1. Menghini R., Menini S., Amoruso R., Fiorentino L., Casagrande V., Marzano V., Tornei F., Bertucci P., Iacobini C., Serino M., et al. (2009). Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136, 663–672.e4
    1. Mouratis M. A., Aidinis V. (2011). Modeling pulmonary fibrosis with bleomycin. Curr. Opin. Pulm. Med. 17, 355–361
    1. Murphy G., Nagase H. (2011). Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J. 278, 2–15
    1. Murthy S., Ryan A., He C., Mallampalli R. K., Carter A. B. (2010). Rac1-mediated mitochondrial H2O2 generation regulates MMP-9 gene expression in macrophages via inhibition of SP-1 and AP-1. J. Biol. Chem. 285, 25062–25073
    1. Onozuka I., Kakinuma S., Kamiya A., Miyoshi M., Sakamoto N., Kiyohashi K., Watanabe T., Funaoka Y., Ueyama M., Nakagawa M., et al. (2011). Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. Biochem. Biophys. Res. Commun. 406, 134–140
    1. Parks W. C., Wilson C. L., López-Boado Y. S. (2004). Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4, 617–629
    1. Ra H. J., Parks W. C. (2007). Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587–596
    1. Radbill B. D., Gupta R., Ramirez M. C., DiFeo A., Martignetti J. A., Alvarez C. E., Friedman S. L., Narla G., Vrabie R., Bowles R., et al. (2011). Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression. Dig. Dis. Sci. 56, 406–416
    1. Raghu G., Weycker D., Edelsberg J., Bradford W. Z., Oster G. (2006). Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174, 810–816
    1. Rock J. R., Barkauskas C. E., Cronce M. J., Xue Y., Harris J. R., Liang J., Noble P. W., Hogan B. L. (2011). Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl. Acad. Sci. USA 108, E1475–E1483
    1. Rosas I. O., Richards T. J., Konishi K., Zhang Y., Gibson K., Lokshin A. E., Lindell K. O., Cisneros J., Macdonald S. D., Pardo A., et al. (2008). MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 5, e93.
    1. Rowe R. G., Lin Y., Shimizu-Hirota R., Hanada S., Neilson E. G., Greenson J. K., Weiss S. J. (2011). Hepatocyte-derived Snail1 propagates liver fibrosis progression. Mol. Cell. Biol. 31, 2392–2403
    1. Sela-Passwell N., Rosenblum G., Shoham T., Sagi I. (2010). Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition? Biochim. Biophys. Acta 1803, 29–38
    1. Seltzre J. L., Eisen A. Z. (1999). Native type I collagen is not a substrate for MMP2 (gelatinase A). J. Invest. Dermatol. 112, 993–994
    1. Sen A. I., Shiomi T., Okada Y., D’Armiento J. M. (2010). Deficiency of matrix metalloproteinase-13 increases inflammation after acute lung injury. Exp. Lung Res. 36, 615–624
    1. Siller-López F., Sandoval A., Salgado S., Salazar A., Bueno M., Garcia J., Vera J., Gálvez J., Hernández I., Ramos M., et al. (2004). Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 126, 1122–1133, discussion 949
    1. Sun L., Louie M. C., Vannella K. M., Wilke C. A., LeVine A. M., Moore B. B., Shanley T. P. (2011). New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. Am. J. Physiol. 300, L341–L353
    1. Takamiya Y., Fukami K., Yamagishi S., Kaida Y., Nakayama Y., Obara N., Iwatani R., Ando R., Koike K., Matsui T., et al. (2013). Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. Nephrol. Dial. Transplant. 28, 55–62
    1. Tam E. M., Moore T. R., Butler G. S., Overall C. M. (2004). Characterization of the distinct collagen binding, helicase and cleavage mechanisms of matrix metalloproteinase 2 and 14 (gelatinase A and MT1-MMP): the differential roles of the MMP hemopexin c domains and the MMP-2 fibronectin type II modules in collagen triple helicase activities. J. Biol. Chem. 279, 43336–43344
    1. Tocchi A., Parks W. C. (2013). Functional interactions between matrix metalloproteinases and glycosaminoglycans. FEBS J. 280, 2332–2341
    1. Uchinami H., Seki E., Brenner D. A., D’Armiento J. (2006). Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 44, 420–429
    1. Vaillant B., Chiaramonte M. G., Cheever A. W., Soloway P. D., Wynn T. A. (2001). Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J. Immunol. 167, 7017–7026
    1. Van den Steen P. E., Proost P., Wuyts A., Van Damme J., Opdenakker G. (2000). Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 96, 2673–2681
    1. Van den Steen P. E., Wuyts A., Husson S. J., Proost P., Van Damme J., Opdenakker G. (2003). Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur. J. Biochem. 270, 3739–3749
    1. Van Lint P., Libert C. (2007). Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol. 82, 1375–1381
    1. Veidal S. S., Karsdal M. A., Vassiliadis E., Nawrocki A., Larsen M. R., Nguyen Q. H., Hägglund P., Luo Y., Zheng Q., Vainer B., et al. (2011). MMP mediated degradation of type VI collagen is highly associated with liver fibrosis—identification and validation of a novel biochemical marker assay. PLoS ONE 6, e24753.
    1. Wang X., Zhou Y., Tan R., Xiong M., He W., Fang L., Wen P., Jiang L., Yang J. (2010). Mice lacking the matrix metalloproteinase-9 gene reduce renal interstitial fibrosis in obstructive nephropathy. Am. J. Physiol. 299, F973–F982
    1. Wang H., Lafdil F., Wang L., Yin S., Feng D., Gao B. (2011). Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production. Cell Biosci 1, 14.
    1. White E. S., Atrasz R. G., Dickie E. G., Aronoff D. M., Stambolic V., Mak T. W., Moore B. B., Peters-Golden M. (2005). Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am. J. Respir. Cell Mol. Biol. 32, 135–141
    1. Wynn T. A. (2004). Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4, 583–594
    1. Wynn T. A. (2008). Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199–210
    1. Wynn T. A. (2011). Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208, 1339–1350
    1. Wynn T. A., Ramalingam T. R. (2012). Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18, 1028–1040
    1. Yamashita C. M., Dolgonos L., Zemans R. L., Young S. K., Robertson J., Briones N., Suzuki T., Campbell M. N., Gauldie J., Radisky D. C., et al. (2011). Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am. J. Pathol. 179, 1733–1745
    1. Yoshiji H., Kuriyama S., Miyamoto Y., Thorgeirsson U. P., Gomez D. E., Kawata M., Yoshii J., Ikenaka Y., Noguchi R., Tsujinoue H., et al. (2000). Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32, 1248–1254
    1. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., Tsujinoue H., Yanase K., Namisaki T., Imazu H., et al. (2002). Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36, 850–860
    1. Yu Q., Stamenkovic I. (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163–176
    1. Yu G., Kovkarova-Naumovski E., Jara P., Parwani A., Kass D., Ruiz V., Lopez-Otín C., Rosas I. O., Gibson K. F., Cabrera S., et al. (2012). Matrix metalloproteinase-19 is a key regulator of lung fibrosis in mice and humans. Am. J. Respir. Crit. Care Med. 186, 752–762
    1. Zuo F., Kaminski N., Eugui E., Allard J., Yakhini Z., Ben-Dor A., Lollini L., Morris D., Kim Y., DeLustro B., et al. (2002). Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl. Acad. Sci. USA 99, 6292–6297

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj